Venous Ulcer
Conditions
Keywords
Venous ulcer, Nexagon, CoDa
Brief summary
Venous leg ulcers are a common, costly and debilitating condition, with few effective treatments. Compression bandaging helps healing, but more than four out of every ten leg ulcers remain unhealed after three months. New treatments to help heal venous ulcers are urgently needed. Initial studies with a new drug product candidate called Nexagon® (developed by CoDa Therapeutics, Inc.) have shown improvements in healing when applied topically to a wound. Further research will be undertaken to assess the safety and activity of Nexagon® when applied to venous leg ulcers in humans, and to obtain further information on the most appropriate dose or doses to apply. A proposed randomised controlled trial aims to further evaluate Nexagon® by randomly allocating (e.g., by the toss of a coin) 90 people with venous leg ulcers to Nexagon® (one of two different doses) or a vehicle (substance containing no medication) to be applied to their ulcer three times over four weeks. Participants will be followed up for 12 weeks to evaluate ulcer healing.
Interventions
DRUGNexagon®
DRUGNexagon® vehicle
Sponsors
OcuNexus Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of venous leg ulceration 2. Ankle brachial index of \> 0.80 measured during screening or within three months prior to the Day -14 visit. 3. Reference ulcer area greater than 1 cm2 and less than 25 cm2 4. Reference ulcer present for at least 4 weeks 5. Have an ankle circumference of greater than 18 cm 6. Male of female patients aged 18 years or over 7. Able to tolerate effective compression bandaging 8. Patients able to walk independently with or without mobility aids 9. Able and willing to give informed consent 10. Able and willing to attend all follow up visits
Exclusion criteria
1. Significant change in ulcer size in the screening period screening period 2. Presence of a non-study ulcer within 2.0 cm of the reference ulcer 3. Wound bed with exposed bone, tendon or fascia 4. Patients with leg ulceration etiology other than venous insufficiency 5. Patients who require wheel chairs for normal mobility 6. Patients who have any ulcer (reference or non-reference) which shows signs of clinical infection 7. Patients who have any ulcer (reference or non-reference) positive for β-hemolytic streptococcus upon culture. 8. Patients who are unable to tolerate or comply with the standardized compression bandaging protocol specified in this protocol 9. Female patients who are pregnant or breastfeeding. 10. Patients who are currently taking: 1. Pentoxifylline (Trental®) 2. Immunosuppressive therapy 3. Oral corticosteroid therapy or topical corticosteroid on the leg where the reference ulcer is located 4. Growth factors (e.g. Regranex) 5. Cell cultures or topical skin factors 11. Patients with: 1. Renal insufficiency defined as an estimated GFR which is \< 30 mL/min/1.7m2 2. Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range 3. Hepatic insufficiency defined as total bilirubin \> 2 mg/dL or serum albumin \< 25 g/L 4. HbA1c \> 8.5% 5. Hemoglobin \< 10 g/dL 6. Hematocrit \< 0.30 7. Platelet count \< 100,000 12. Patients have had a myocardial infarction within the previous 6 months or patients with unstable angina pectoris 13. Patients with: 1. Collagen vascular disease 2. Severe rheumatoid arthritis 3. Cellulitis or osteomyelitis 14. Patients who have, or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment 15. Patients who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study, e.g., known to abuse alcohol or drugs currently or to have psychological disorders that could affect follow-up care
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of reduction in the size of the reference ulcer from Day 0 to Day 28 as measured by photographic planimetry | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete healing of the treated Venous Leg Ulcer | — |
| Reference ulcer wound healing as assessed by digital photographic planimetry | — |
| Adverse Events | — |
Countries
New Zealand, United States
Outcome results
None listed